Karyopharm Therapeutics Inc. (KPTI) Fair Value 2026

KPTI · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.8 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (32/100)

Quick Summary — As of 2026-08-28, Karyopharm Therapeutics Inc. (KPTI) trades at $1.87. QOC: 4.8/10. Value Trap Risk: 32/100 (LOW). 1/13 models active.

Key Facts

Ticker
KPTI
Price
$1.87
Quality Score
4.8/10
Value Trap Risk
32/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +65.0% upside with 29% confidence
Risk: Below-average Quality Score of 4.8/10 signals weak fundamentals

What Fair Value Does Each Model Give KPTI?

1 Intrinsic Value Models vs. Current Price ($1.87)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $3.08 +65.0%

All Models Active

All 1 models are displayed above.

What Is Karyopharm Therapeutics Inc. (KPTI) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Karyopharm Therapeutics Inc.. Trading at $1.87 against an estimated intrinsic value of $3.08, 1 of 1 active models flag meaningful upside of +65.0% at the median.

What Do the Models Say About KPTI?

1 of 13 models are currently active for KPTI. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does KPTI Rank in Biotechnology?

Among 625 Biotechnology stocks, KPTI ranks #370 by Quality of Company score. CirclFi's QOC score of 4.8/10 evaluates 32 fundamental signals. A score of 4.8 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotech businesses. For Karyopharm Therapeutics Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is KPTI a Value Trap?

CirclFi's Value Trap algorithm assigns KPTI a score of 32/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Karyopharm Therapeutics Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Karyopharm Therapeutics Inc. scores 4.8 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every KPTI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across KPTI's 1 active models, average confidence is 29%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Karyopharm Therapeutics Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

INTIInhibitor Therapeutics, Inc.QOC 4.8VKTXViking Therapeutics, Inc.QOC 4.8NAUTNautilus Biotechnology, Inc.QOC 4.8TRVITrevi Therapeutics, Inc.QOC 4.8INTSIntensity Therapeutics, Inc.QOC 4.8SNGXSoligenix, Inc.QOC 4.8QNRXQuoin Pharmaceuticals, Ltd.QOC 4.1FDMT4D Molecular Therapeutics, Inc.QOC 6.8ASBPAspire Biopharma Holdings, Inc.QOC 5.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: INTI · VKTX · NAUT · TRVI · INTS · SNGX · QNRX · FDMT · ASBP · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to KPTI?

4 companies across all industries closest to KPTI’s Quality of Company score of 4.8/10.

KPEAKun Peng International Ltd.QOC 4.8HLEOHelio CorporationQOC 4.8CHRNChronoScale Holdings CorporationQOC 4.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: KPEA · HLEO · CHRN · NVDA

Where Does KPTI Sit in CirclFi's Biotechnology Rankings?

KPTI is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Karyopharm Therapeutics Inc.’s Valuation?

What is Karyopharm Therapeutics Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Karyopharm Therapeutics Inc. (KPTI). The Quality of Company score is 4.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is KPTI overvalued or undervalued right now?

At $1.87, 1 of 1 active models suggest KPTI may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Karyopharm Therapeutics Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.8 mean for KPTI?

Karyopharm Therapeutics Inc.'s QOC of 4.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on KPTI?

CirclFi analyzes KPTI with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is KPTI a value trap in 2026?

Karyopharm Therapeutics Inc.'s Value Trap score is 32/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Karyopharm Therapeutics Inc. (KPTI) a Quality of Company score of 4.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/KPTI/ · Methodology
Primary sources for this KPTI valuation
  • Financial statements: Karyopharm Therapeutics Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001503802) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for KPTI as of ; valuations recomputed .